论文部分内容阅读
化疗是晚期肺癌的主要治疗手段,第三代新药联合铂类的两药化疗方案是初治晚期非小细胞肺癌(NSCLC)的标准一线治疗方案,与最佳支持治疗比较,中位生存期延长2个月,1年生存率提高10%。
Chemotherapy is the main treatment for advanced lung cancer. The third-generation new drug combined with platinum-based two-drug chemotherapy regimen is the standard first-line treatment for advanced non-small cell lung cancer (NSCLC). Compared with the best supportive care, the median survival time 2 months, 1 year survival rate increased by 10%.